Inter Partes Review Proceedings
PTAB Portal
IPR Case No(s):
U.S. Patent No.
6,627,196 (Dosages for Treatment with Anti-ErbB2 Antibodies)
Patent Owner
Genentech, Inc.
Petitioner(s)
Samsung Bioepis, Co., Ltd.
§ 102 Challenge
N
§ 103 challenge
Y
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y; Joined with IPR2017-00804
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
19-1174
IPR Status
Joined with IPR2017-00804; Final Written Decision (No Instituted Claim Found Unpatentable); Federal Circuit Appeal Dismissed
U.S. Patent No.
7,371,379 (Dosages for Treatment with Anti-ErbB2 Antibodies)
Patent Owner
Genentech, Inc.
Petitioner(s)
Samsung Bioepis, Co., Ltd.
§ 102 Challenge
N
§ 103 challenge
Y
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y; Joined with IPR2017-00805
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
19-1173
IPR Status
Joined with IPR2017-00805; Final Written Decision (No Instituted Claim Found Unpatentable); Federal Circuit Appeal Dismissed
U.S. Patent No.
7,892,549 (Treatment with Anti-ErbB2 Antibodies)
Patent Owner
Genentech, Inc.
Petitioner(s)
Samsung Bioepis, Co., Ltd.
§ 102 Challenge
N
§ 103 challenge
Y
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y; Joined with IPR2017-00737
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
19-1265
IPR Status
Joined with IPR2017-00737; Final Written Decision (All Instituted Claims Found Unpatentable); Federal Circuit Appeal Terminated as to Hospira, Motion for Samsung Bioepis to Withdraw as a Party Granted, Ongoing with USPTO Director as Intervenor
U.S. Patent No.
6,407,213 (Method for Making Humanized Antibodies)
Patent Owner
Genentech, Inc.
Petitioner(s)
Samsung Bioepis, Co., Ltd.
§ 102 Challenge
Y
Claim Types Challenged Under § 102
Composition of Matter
§ 102 Challenge Instituted
Y; Joined with IPR2017-01488
§ 103 challenge
Y
Claim Types Challenged Under § 103
Composition of Matter
§ 103 Challenge Instituted
Y; Joined with IPR2017-01488
Final Written Decision Issued
Y
IPR Status
Joined with IPR2017-01488; Final Written Decision (Some Instituted Claims Found Unpatentable)
U.S. Patent No.
6,407,213 (Method for Making Humanized Antibodies)
Patent Owner
Genentech, Inc.
Petitioner(s)
Samsung Bioepis, Co., Ltd.
§ 102 Challenge
N
§ 103 challenge
Y
Claim Types Challenged Under § 103
Composition of Matter
§ 103 Challenge Instituted
Y; Joined with IPR2017-01489
Final Written Decision Issued
Y
IPR Status
Joined with IPR2017-01489; Final Written Decision (Some Instituted Claims Unpatentable)
U.S. Patent No.
7,846,441 (Treatment with Anti-ERBB2 Antibodies)
Patent Owner
Genentech, Inc.
Petitioner(s)
Samsung Bioepis, Co., Ltd.
§ 102 Challenge
N
§ 103 challenge
Y
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
N
IPR Status
IPR Not Instituted
FDA-Approved Indications
Approved Foreign Follow-On Biologics / Biosimilars
U.S. Patent Litigations
